There is provided legumain targeting lipids includes lipid binding legumain bookbinding part, and wherein the legumain bound fraction includes that azepine ASN peptides type reactivity part legumain inhibitor has formula (I) compound. Further providing for legumain targeted nano-particle composition includes the lipid material that lipid nano particle includes the above-mentioned mixing of legumain targeting lipids and other one or more micellas or micro-capsule. Drug can be encapsulated in particle. Lipid is designed to which overexpression and tumour legumain anti-cancer agent.
